id: NEW:oral_nicotine_pouch_use_to_smoking_current
name: Oral Nicotine Pouch Use â†’ Current Smoking Status
from_node:
  node_id: NEW:oral_nicotine_pouch_use
  node_name: Oral Nicotine Pouch Use
to_node:
  node_id: smoking_current
  node_name: Current Smoking Status
direction: negative
category: behavioral
mechanism_pathway:
- 'Step 1: Oral nicotine pouches deliver nicotine without tobacco combustion'
- 'Step 2: Users may substitute cigarettes with pouches'
- 'Step 3: Reduced cigarette consumption during substitution period'
- 'Step 4: Potential complete transition away from combustible tobacco'
evidence:
  quality_rating: C
  n_studies: 4
  primary_citation: Jamie Hartmann-Boyce et al. 2025. "Oral nicotine pouches for cessation or reduction
    of use of other tobacco or nicotine products.." https://doi.org/10.1002/14651858.CD016220.pub2
  supporting_citations:
  - Additional citations require full-text access - 4 RCTs included in review
  - Total participants n=284 across all studies
  - Studies compared ONP to various controls including e-cigarettes, snus, and NRT
  doi: 10.1002/14651858.CD016220.pub2
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Low-certainty evidence suggests people randomized to ONP may be slightly less likely to quit
  smoking than those randomized to e-cigarettes, indicating ONP may be less effective as a cessation tool
  compared to vaping products
quantitative_effects:
  effect_size:
    value: 0.25
    type: relative_risk
    ci_lower: 0.03
    ci_upper: 2.02
  sample_size: 36
moderators:
- name: alternative_nicotine_product_type
  direction: weakens
  strength: moderate
  description: E-cigarettes may be more effective than ONP for smoking cessation (ONP showed lower abstinence
    rates compared to e-cigarettes)
structural_competency:
  equity_implications: Differential effectiveness of harm reduction products has policy implications for
    tobacco control strategies. If e-cigarettes are more effective, regulatory frameworks that restrict
    e-cigarettes while permitting ONP may not optimize population health outcomes. Market availability
    and regulatory stringency represent structural determinants of cessation success.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:36.886885'
  extraction_confidence: low
  prompt_version: 2.1-canonical-validated
